Lipocine Inc. (LPCN)

↓ Download CSV

CIK 0001535955 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Lipocine Inc. reported revenue of $1.98M, down 82.3% from the prior year. The company ran a net loss, with a net margin of -487.1%. It held $17.01M in total assets against $2.53M in total liabilities.

Key ratios (FY2025)

-524.7%
Operating margin
-487.1%
Net margin
-66.5%
Return on equity
-82.3%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$1.98M$11.20M-$2.85M$500.0K$16.14M$0$165.0K$428.0K$0$0
Operating Income-$10.37M-$1.16M-$17.93M-$12.12M$3.15M-$18.00M-$12.90M-$11.33M-$21.22M-$19.19M
Net Income-$9.63M$8.4K-$16.35M-$10.76M-$634.4K-$20.96M-$13.01M-$11.66M-$20.98M-$18.97M
EPS (Diluted)$-1.69$-3.14$-2.15$-0.01$-0.38$-0.50$-0.55$-1.05$-1.04
Total Assets$17.01M$22.51M$23.00M$37.54M$52.48M$25.35M$19.66M$20.85M$25.33M$27.34M
Total Liabilities$2.53M$1.51M$2.63M$1.91M$6.91M$10.01M$13.37M$11.42M$6.35M$1.33M
Shareholders' Equity$14.48M$21.00M$20.37M$35.63M$45.57M$15.34M$6.29M$9.43M$18.98M$26.02M
Cash & Equivalents$5.21M$6.21M$4.77M$3.15M$2.95M$19.22M$9.73M$8.08M$3.21M$5.56M
Operating Cash Flow-$9.76M-$1.22M-$11.87M-$11.97M-$4.41M-$15.30M-$11.67M-$12.08M-$16.70M-$18.28M
Capital Expenditures$90.1K$13.2K$133.8K$7.6K$0$0$59.6K
Shares Outstanding6.16M5.35M5.32M5.23M88.29M70.04M37.65M21.73M21.26M18.46M